REMUS PHARMACEUTICALS L Valuation
REMUS · Healthcare · Current price ₹734.1
Is REMUS PHARMACEUTICALS L undervalued?
DocStoX estimates the fair value of REMUS PHARMACEUTICALS L at ₹509 per share, versus the current market price of ₹734. That puts the stock about -30.7% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹301), Relative P/E (₹952), Graham floor (₹459). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹301 (bear) to ₹509 (base) to ₹952 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Valuation multiples
REMUS PHARMACEUTICALS L trades at a P/E of 23.4x and a P/B of 2.5x, with a dividend yield of 0.1%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
Understand the ratios
More on REMUS PHARMACEUTICALS L
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.